Immutep Quarterly Activities Report Q2 FY25
Media ReleaseMarking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer ...
Pharmabiz5h
Aethlon announces first patient enrolled and treated with the Hemopurifier at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital
Aethlon announces first patient enrolled and treated with the Hemopurifier at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital: San Diego Friday, January 31, 2025, 1 ...
Advanced Cervical Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight
DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ ...
Shorter, safer protocol can effectively treat triple-negative breast cancer
A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...
precisionmedicineonline21h
Opdivo, Yervoy Outperform Single-Agent Immunotherapy in First-Line MSI-High, dMMR Colorectal Cancer
Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.